Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

AN2 Therapeutics Inc ANTX

Healthcare
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.


NDAQ:ANTX - Post by User

AN2 Therapeutics Inc
<< Previous
 Bullboard Posts
User Avatar Image
(267)
•••
Post by whytestockson Feb 12, 2024 6:30pm
76 Views
Post# 35876491

AN2 Therapeutics Investigated by Block & Leviton For Potenti

AN2 Therapeutics Investigated by Block & Leviton For Potenti
NEWS: $ANTX AN2 Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm | BenzingaBOSTON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Block &amp; Leviton is investigating AN2 Therapeutics, Inc. (NASDAQ:ANTX) for potential securities law...ANTX - AN2 Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm | Benzinga


<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities